

# Connectomics of orexin-producing neurons: interface of systems of emotion, energy homeostasis and arousal

|                                 |   |
|---------------------------------|---|
| 著者                              | Sakurai Takeshi, Mieda Michihiro  |
| journal or<br>publication title | Trends in Pharmacological Sciences  |
| volume                          | 32  |
| number                          | 8   |
| page range                      | 451-462   |
| year                            | 2011-08-01  |
| URL                             | <a href="http://hdl.handle.net/2297/28327">http://hdl.handle.net/2297/28327</a> |

doi: 10.1016/j.tips.2011.03.007

# Connectomics of Orexin-producing Neurons: Interface of Systems of Emotion, Energy

## Homeostasis and Arousal

Takeshi Sakurai and Michihiro Mieda

Department of Molecular Neuroscience and Integrative Physiology, Faculty of Medicine, Kanazawa

University, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8640, Japan

e-mail: [tsakurai@med.kanazawa-u.ac.jp](mailto:tsakurai@med.kanazawa-u.ac.jp)

Tel: +81-76-265-2173

Fax: +81-76-234-4224

### Abstract

Avoiding danger and finding food, which are life-sustaining activities that are regulated by emotion, reward and energy balance, require proper wakefulness. The orexin system regulates sleep and wakefulness through interactions with systems that regulate emotion, reward and energy homeostasis. This system regulates sleep and wakefulness to occur at appropriate times that are in accordance with our internal and external environments. Recent findings have brought about the possibility of novel therapies targeting orexin

system for sleep disorder including insomnia and narcolepsy-cataplexy. In this review, we will discuss the current understanding of the integrative physiology and clinical perspectives of the orexin system.

## Glossary

### **Ascending reticular activating system**

The ascending reticular activating system is a concept originally proposed by Moruzzi & Magoun in 1949. They found that stimulation at the core of the reticular formation in the brain stem is effective in inducing desynchronization pattern of the EEG in cat, suggesting this stimulation cause cortical arousal. Lesion of the reticular formation produced chronic EEG inactivation and somnolence. These studies introduced the concept that cortical activation was actively maintained by the tonic activation of brainstem core neurons. Currently, it is commonly considered that the reticular activating system is composed of several ascending pathways including monoaminergic and cholinergic neurons in the brain stem.

### **Narcolepsy**

Neurological condition most characterized by excessive daytime sleepiness, episodes of sleep and disorder of REM or rapid eye movement sleep.

### **Cataplexy**

Episodic condition featuring loss of muscle function, ranging from slight weakness (such as limpness at the neck or knees, sagging facial muscles, or inability to speak clearly) to complete body collapse. Cataplexy is often observed in narcolepsy patients.

### **Non-rapid eye movement (NREM) sleep**

Sleep is a cyclic process. Under normal conditions, sleep is characterized by regular alternation between rapid eye movement sleep (REM) and non-rapid eye movement sleep (NREM). NREM sleep is divided into 4 stages; Stages 1 and 2 are characterized by low arousal thresholds and are considered light sleep. Stages 3 and 4 are characterized by high arousal thresholds and are considered deep or “slow wave” sleep. All 4 of these stages can be differentiated by electroencephalography (EEG). Stage 1 is marked by low voltage, mixed frequency EEG. Stage 2 is marked by the presence of K complexes and sleep spindles on EEG recordings. Both stages 3 and 4 are marked by delta waves, which have a voltage of 75 microvolts or more and a frequency range of 0.5 to 4 hertz, but differ in composition. Stage 3 is defined as sleep consisting of 20-50% delta waves and stage 4 as sleep consisting of more than 50% delta waves.

**Rapid eye movement (REM) sleep**

The stage of sleep characterized by rapid movements of the eyes. It was identified and defined by Nathaniel Kleitman and Eugene Aserinsky in 1953. Criteria for REM sleep includes low muscle tone and a rapid, low-voltage EEG. REM sleep in adult humans typically occupies 20–25% of total sleep, about 90–120 minutes of a night's sleep.

**ventrolateral preoptic nucleus (VLPO)**

The ventrolateral preoptic nucleus (VLPO) is a region of the anterior hypothalamus, which includes sleep-active neurons, which inhibit the major ascending monoaminergic arousal systems during sleep.

**Lateral hypothalamic area (LHA)**

The lateral hypothalamus or lateral hypothalamic area is a region of the hypothalamus, generally including the lateral hypothalamic area and lateral preoptic nucleus. Classically, this region is considered as a feeding center. Stimulation of this area causes increased food intake, while bilateral lesion of this area causes cessation of feeding. This region receives input from amygdala. This area contains glucose sensitive neurons, which are inhibited by glucose. This region are also critically involved in the regulation of sympathetic nerve function and arousal.

## Introduction

Feeding behavior is greatly affected by emotion, reward and energy balance. Simultaneously, it requires proper wakefulness and vigilance. Regulatory centers of feeding and energy homeostasis are believed to be localized within the hypothalamus, whereas the most critical neuronal network for wakefulness is the ascending reticular activating system (ARAS) in the brainstem that sends projections to multiple areas of the forebrain. These observations suggest the existence of a neuronal system that acts as a link between the feeding centers in the hypothalamus and the brainstem "waking center". Recent evidence clearly suggests that orexin-producing neurons in the hypothalamus are crucial for such linkage.

Orexin A and orexin B (also known as hypocretin 1 and hypocretin 2) are hypothalamic neuropeptides that were discovered thirteen years ago. Initially, these peptides were recognized as regulators of feeding behavior<sup>1</sup>. Subsequently, several studies suggested that orexin deficiency causes narcolepsy in humans and other mammalian species, highlighting roles of this hypothalamic neuropeptide in the regulation of sleep and wakefulness<sup>2</sup>. Studies of efferent and afferent systems of orexin-producing neurons have shown that the orexin neuronal system has close interactions with systems that regulate emotion, energy homeostasis, reward, and arousal<sup>3-10</sup>.

These observations suggest that orexin neurons are involved in sensing the body's external and internal environments, and regulate vigilance states accordingly. In this review, we will discuss the mechanisms by which the orexin system regulates wakefulness in relation to energy homeostasis and other systems. We will also discuss the therapeutic potential of drugs that target orexin receptors.

## Orexin and orexin receptors

In 1998, our research team identified novel neuropeptides, orexin A and orexin B, from rat brain extracts as two endogenous ligands for two orphan G-protein-coupled receptors by a method called "reverse pharmacology"<sup>1</sup>. Molecular cloning studies showed that both orexin A and orexin B are derived from a common precursor peptide, *prepro-orexin* (Figure1). An mRNA encoding the same precursor peptide was independently identified by de Lecea *et al.* as a hypothalamus-specific transcript<sup>11</sup>. The authors predicted that the transcript encoded a polypeptide precursor that is cleaved to form two neuropeptides, termed hypocretin-1 and hypocretin-2 (corresponding to orexin A and orexin B, respectively). Orexin A and orexin B constitute a novel distinct peptide family, showing no significant homology with any previously described peptides<sup>12</sup>. Structural analysis of purified peptide showed that orexin A is a 33-amino-acid peptide with an N-terminal pyroglutamyl residue, two intra-chain disulfide bonds, and C-

terminal amidation. This structure is completely conserved among several mammalian species (human, rat, mouse, cow, sheep, dog and pig). Orexin B is a 28-amino-acid, C-terminally amidated linear peptide. Amino acid sequences of various species of orexin B show that there are several species differences, although highly conserved. The C-terminal half of orexin B is very similar to that of orexin A, whereas the N-terminal half is more variable.

The actions of orexins are mediated via two G-protein coupled receptors (GPCRs), orexin 1 (OXR-1) and orexin 2 (OXR-2) receptors (also known as Hcrtr1 and Hcrtr2). OXR-1 has one-order-of-magnitude greater affinity for orexin A over orexin B. In contrast, OXR-2 accepts both ligands with similar affinities<sup>1</sup>. OXR-1 couples to G<sub>q/11</sub> class of G-protein, which results in activation of phospholipase C to trigger of the phosphatidylinositol cascade and influx of extracellular Na<sup>+</sup> and Ca<sup>2+</sup>, presumably through TRP channels to cause depolarization of neurons. OXR-2 couples to both G<sub>q/11</sub> or G<sub>i</sub>-classes of G-proteins in a neuronal cell line<sup>13</sup>. *OXR-1* and *OXR-2* mRNAs exhibit a markedly different and basically complementary distribution, suggesting that these receptors have distinct physiological roles through different neuronal pathways<sup>14</sup>.

Orexin neurons, which have been assumed to number around 3,000 in rat brains, or 70,000 in human brains<sup>15-16</sup>, are localized exclusively in the hypothalamus, including



the lateral hypothalamic area (LHA), perifornical area, and posterior hypothalamus (PH)

15-17 .

## Implication of orexins in the pathophysiology of narcolepsy

### *What is narcolepsy?*

An understanding of narcolepsy, a sleep disorder that results from loss of orexin neurons, provides insight into the physiological functions of orexins. Narcolepsy is a debilitating neurological disorder that affects approximately 1 in 2000 individuals in the United States<sup>18</sup>. A cardinal symptom of the disorder is excessive daytime sleepiness (an insurmountable urge to sleep), which often results in falling asleep at inappropriate times and situations ('sleep attack'). The latency for rapid eye movement (REM) sleep is notably reduced in narcolepsy patients, and the existence of 'sleep-onset REM periods' (i.e. REM-sleep is directly preceded by an awake period) is one of the diagnostic criteria for narcolepsy. Nocturnal sleep is often disturbed by sleep fragmentation combined with the occurrence of hypnagogic hallucinations, vivid dreaming, and sleep paralysis, which usually occur immediately after patients fall asleep. Narcolepsy patients often suffer from a condition called "cataplexy", which is a sudden weakening of muscle tone, ranging from jaw dropping and speech slurring to complete

bilateral collapse of the postural muscles. Usually, cataplexy is triggered by emotional stimuli. Unlike the sleep attack, consciousness is preserved during cataplexy. Narcolepsy with cataplexy is sometimes referred as “narcolepsy-cataplexy”.

Thus, narcolepsy is characterized by the inability to maintain wakefulness states, pathological intrusion of REM sleep into wakefulness, and frequent transitions between states of sleep and wakefulness, which suggests that orexins have important roles in the maintenance and stabilization of sleep and wakefulness and REM sleep regulation.

### ***Roles of orexins in pathophysiology of narcolepsy***

The first clues that orexins are involved in narcolepsy came from animal models. Mice lacking the *orexin* gene or dogs with null mutations in *OXR-2* show phenotypes remarkably similar to human narcoleptic patients<sup>19-20</sup>. *Prepro-orexin* knockout (KO) mice, orexin neuron-ablated (*orexin/ataxin-3*-transgenic) mice, and *OXR-1/OXR-2* double KO mice show similar phenotypes that have strong parallels to the human condition, characterized by behavioral arrests that are similar to cataplexy, occasional direct transitions to REM sleep from wakefulness, and highly fragmented sleep-wake cycles<sup>19,21</sup>, all of which are important elements of narcolepsy.

The link between orexin dysfunction and narcolepsy (especially if narcolepsy-cataplexy) has since been supported by studies with human patients. A postmortem

study of human narcolepsy subjects showed no detectable levels of orexin peptides in the cortex and pons, in which normally orexinergic projections are found (Figure 2A), and an 80-100% reduction in the number of neurons containing detectable *prepro-orexin* mRNA or orexin-like immunoreactivity in the hypothalamus<sup>22-23</sup>. Approximately 90% of patients with narcolepsy are shown to have decreased orexin A levels in the cerebrospinal fluid<sup>24</sup>. Therefore, a low CSF level of orexin A (less than 110 pg/ml) is now one of the diagnostic criteria for narcolepsy-cataplexy according to the 2nd edition of the international classification of sleep disorders<sup>25</sup>.

Because of its strong association with certain human leukocyte antigen(HLA) alleles<sup>26</sup>, it has been speculated that narcolepsy results from selective immune-mediated degeneration of orexin neurons. Recently, Tribbles homolog 2 (Trib2) was reported as a possible antigen involved in the autoimmune destruction of orexin neurons<sup>27</sup>. Trib2 was abundantly expressed in orexin neurons, and levels of Trib2-specific antibodies were much greater in people with narcolepsy. Recent studies also reported that susceptibility to narcolepsy is associated with single nucleotide polymorphisms (SNPs) in the T-cell receptor alpha locus<sup>28</sup> and those located between the *carnitine palmitoyl-transferase 1B* and *choline kinase beta*<sup>29</sup>.

Regardless of the cause of the neuronal loss, the orexin signaling deficiency in

narcolepsy-cataplexy shows that this neuropeptide system plays an important role in the regulation of sleep and wakefulness, especially in the maintenance of long, consolidated awake periods.

### ***Pathological Contribution of Each Receptor Subtype***

Narcolepsy can be divided into two pathological phenomena, suggesting that pathophysiology of narcolepsy is caused by two independent mechanisms. One is a difficulty in maintaining long awake periods, characterized by abrupt transitions from wakefulness to NREM sleep (dysregulation of NREM sleep onset). This phenomenon manifests clinically as excessive daytime sleepiness, which sometimes results in sleep attacks. Mouse studies suggested that it largely results from a lack of OXR-2 signaling<sup>30</sup>. Psychostimulant drugs, such as modafinil, methyl phenidate, amphetamine and caffeine are used to treat these symptoms.

The other key phenomenon is the pathological intrusions of REM sleep into wakefulness (dysregulation of REM sleep onset); it is during these periods that the patient might experience cataplexy, hypnagogic hallucinations, sleep paralysis. Available therapy for this symptom consists of tricyclic antidepressants such as imipramine and serotonin-specific reuptake inhibitors (SSRIs)<sup>31</sup>, suggesting existence of abnormal monoaminergic neurotransmission in cataplexy. Lack of signaling from both

receptors is critically associated with this symptom<sup>32-33</sup>.

## Input to orexin neurons

Recent studies using anterograde and retrograde tracers suggest that orexin neurons receive abundant projections from the lateral septum, the preoptic area, the amygdala, the bed nucleus of the stria terminalis (BNST), the posterior/dorsomedial hypothalamus, and the serotonergic neurons in the raphe nuclei<sup>7-8</sup>.

### *Input from limbic system*

Abundant input from the limbic system<sup>7-8, 34</sup> (which is implicated in emotion) suggests it plays a part in the regulation of the firing rate of orexin neurons. Indeed, the importance of this connection is apparent in the defense (or "fight or flight") response. Mice tested in a resident-intruder paradigm show cardiovascular and locomotor responses to emotional stress, but these responses are diminished in *prepro-orexin* KO mice<sup>35</sup>. Similarly, air-jet stress-induced elevations of blood pressure and heart rate were attenuated in conscious *orexin/ataxin-3* transgenic mice, in which orexin neurons are genetically ablated<sup>36</sup>. Furthermore, in urethane-anesthetized mice, microinjection of the GABA<sub>A</sub> receptor antagonist bicuculline into the amygdala or BNST increased Fos immunoreactivity in orexin neurons and induced long-lasting and dose-dependent cardiorespiratory excitation in wild-type mice. By contrast, in *orexin-ataxin 3* mice,

cardiorespiratory responses after disinhibition of the amygdala were not observed and those after activation of the BNST were attenuated. These observations suggest that orexin-containing neurons mediate at least a part of amygdala- and BNST-induced increases in the sympathetic outflow<sup>37</sup>.

The lower level of activation of the sympathetic out flow by emotional stimuli, might affect the establishment of emotional memory, because emotional reaction has been known to be strongly affected by sympathetic responses. Abnormality of amygdala function was recently reported in human narcolepsy patients, using functional MRI (fMRI) imaging<sup>38</sup>. The study reported no enhancement of amygdala response to conditioned stimuli and no increase in functional coupling between the amygdala and medial prefrontal cortex. These findings suggest that human narcolepsy is accompanied by abnormal emotional learning, and that, in line with animal data, the orexin system is critical for the function of the amygdala in this process.

The neural input from the limbic system to orexin neurons is also implicated in pathophysiology of cataplexy, because strong, generally positive emotional stimuli are well known to trigger cataplexy in narcolepsy-cataplexy patients. Local injection of orexin into the pedunculopontine tegmental nucleus (PPT) strongly inhibited REM-related atonia in cats<sup>39</sup>. These cholinergic neurons are implicated in REM-related

tonia<sup>40</sup> and the same pathway is implicated in cataplexy. Therefore, through excitatory influences from the limbic system, emotional stimuli might increase orexin release in the PPT to prevent muscle atonia in wild-type animals. Mechanisms of action of orexin in the PPT/laterodorsal tegmental nucleus (LDT) will be further discussed below. In addition to the suppression of muscle atonia, activation of orexin neurons by the limbic system is likely to maintain wakefulness during emotional arousal by conveying various emotional stimuli to orexin neurons.

The limbic input to orexin neurons might also be involved in the regulation of feeding behavior. Some of the affective content of the perception of food is thought to be processed in the amygdala and limbic system<sup>41</sup>, and this information might be passed on to orexin neurons. Food perception often evokes cataplexy in narcoleptic dogs<sup>42</sup>, suggesting that orexin signaling is physiologically activated upon perception of food, and that this system is necessary to evoke proper feeding behavior including the maintenance of motor activity.

### ***Input from preoptic areas***

The preoptic area, especially the ventrolateral preoptic nucleus (VLPO) and median preoptic nucleus (MPO), appears to play a crucial role in NREM sleep initiation and maintenance. Some neurons in the VLPO are sleep-active neurons, which fire at a rapid

rate during sleep and show attenuation of firing during wakefulness. GABA and galanin are the primary inhibitory neurotransmitters of the VLPO<sup>43</sup>, which sends out multiple inhibitory projections onto the locus coeruleous (LC), tuberomammillary nucleus (TMN), and dorsal raphe (DR)<sup>43-44</sup>. Orexin neurons, which are strongly inhibited by both the GABA<sub>A</sub> agonist muscimol and the GABA<sub>B</sub> receptor agonist baclofen<sup>4,45</sup>, are innervated by GABA-containing cells in the VLPO<sup>7-8</sup>. This pathway might be important for turning off orexin neurons during sleep (Figure 2B). Selective disruption of GABA<sub>B</sub> receptor in orexin neurons resulted in severe fragmentation of sleep/wake states during both light and dark periods, suggesting GABA<sub>B</sub> receptor-mediated regulation of orexin neurons play an important role in sleep/wake maintenance<sup>46</sup>.

### ***Input from the brainstem regions***

Orexin neurons receive inhibitory projections from the raphe nuclei<sup>47-48</sup>. An electrophysiological study showed that orexin neurons are also inhibited by noradrenalin<sup>49</sup>. As described later, serotonergic neurons in the raphe nuclei and noradrenergic neurons in the LC have been considered crucial for wakefulness and receive dense excitatory projections of orexin neurons. Thus, these observations suggest that orexin neurons and monoaminergic neurons constitute negative feedback loop



circuitry, which might play important parts in the maintenance of firing rates of each component within appropriate ranges (Fig. 2B).

### ***Factors that regulate orexin neurons***

In addition to the classical neurotransmitters, glutamate and GABA, several neurotransmitters/neuromodulators have been shown to influence the firing rate of orexin neurons. Both noradrenaline and serotonin (5HT) hyperpolarize and inhibit GFP-expressing orexin neurons through the activation of G protein-regulated inwardly rectifying K<sup>+</sup> (GIRK or Kir3) channels via  $\alpha_2$ -adrenoceptors and 5HT<sub>1A</sub>-receptors, respectively<sup>49-51</sup>. The cholinergic agonist carbachol activates 27% and inhibits 6% of orexin neurons<sup>7, 51</sup>, whereas histamine does not have any effect on orexin neurons. Although orexin neurons do not express functional dopamine receptors, dopamine can inhibit orexin neurons by acting on  $\alpha_2$ -adrenoceptors<sup>49, 51</sup>. Several neuropeptides, including cholecystinin (CCK-8S), neurotensin, oxytocin, and vasopressin, induce depolarization and excitation of orexin neurons<sup>52</sup>. A synthetic surrogate ligand for an orphan receptor, BRS-3, also activates these neurons<sup>53</sup>. Recently, orexin itself was shown to activate orexin neurons through OXR-2, suggesting a positive feed back mechanism that maintain orexin neuronal activity<sup>54</sup>.

Interestingly, metabolic signals also contribute to the regulation of firing rate of

orexin neurons: decreasing the extracellular glucose concentration produced depolarization and increased the frequency of firing of orexin neurons, whereas increasing glucose concentration induced hyperpolarization and cessation of firing<sup>4, 55</sup>. Importantly, this mechanism is sufficiently sensitive to encode variations in glucose levels in cerebrospinal fluid reflecting those occurring physiologically between normal meals<sup>4, 55</sup>. These responses were shown to be mediated by tandem-pore K<sup>+</sup> (K<sub>2P</sub>) channels<sup>56</sup>. In addition, hypoglycemic signals transmitted via vagal afferents and the nucleus of the solitary tract (NTS) were also shown to inhibit orexin neurons<sup>57-58</sup>.

Ghrelin, a stomach-derived orexigenic peptide, activated 60% of dispersed orexin neurons with depolarization and an increase in firing frequency<sup>4</sup>. By contrast, bath-application of leptin, an anorexigenic protein hormone secreted by adipocytes, was found to robustly inhibit most of the orexin neurons examined, causing hyperpolarization and a decrease in firing rate<sup>4</sup>.

These findings show that peripheral humoral factors that are related to energy metabolism influence the activity of orexin neurons. In addition, orexin expressions in wild-type and *ob/ob* mice are negatively correlated with changes in blood glucose, leptin, and food intake<sup>4</sup>. These observations support the idea that orexin neurons act as a sensor of the nutritional status<sup>1, 4, 12</sup>.

This suggests that nutritional depletion-induced metabolic cues activate orexin neurons to increase arousal, thereby reinforcing food-seeking/feeding pathways. Consistently, orexin neuron-ablated mice fail to exhibit this fasting-induced arousal<sup>4</sup>, suggesting that orexin neurons are necessary for evoking adaptive behavioral arousal during fasting. The mechanism that helps to ensure survival in nature clearly involves orexins, and might hinder attempts to treat obesity by food restriction. This might also explain why orexin receptor antagonists decrease food intake (see below)<sup>59</sup>.

## Output of orexin neurons

Orexin-immunoreactive fibers were observed in the almost entire neuroaxis, excluding the cerebellum<sup>15-17</sup>. The densest staining of fibers is found in the paraventricular nucleus of the thalamus, arcuate nucleus (Arc) of the hypothalamus, and most notably, monoaminergic nuclei in the brain stem regions, including the LC (containing noradrenergic neurons), raphe nuclei (containing serotonergic neurons), TMN (containing histaminergic neurons), and LDT/PPT (containing cholinergic neurons)<sup>16-17</sup>.<sup>22</sup> The distribution of the orexin receptor mRNA is consistent with these projection sites; within the brain, *OXR-1* is most abundantly expressed in the LC, while *OXR-2* is highly expressed in the TMN<sup>14</sup>. Both regions are important for the maintenance of

arousal<sup>14</sup>. The raphe nuclei, LDT/PPT, and ventral tegmental area (VTA) contain both *OXR-1* and *OXR-2*<sup>14</sup>, although they are expressed in distinct neuronal populations in each region<sup>33</sup> (Further discuss later). These observations suggest that these monoaminergic regions, implicated in the regulation of wakefulness, are major effector sites of orexins (Figure 2).

These monoaminergic neurons diffusely innervate the forebrain. Their projections are thought to be involved in the ARAS, and have been shown to play important roles in promoting arousal. Pontine neurons that produce acetylcholine (ACh) in PPT/LDT are also important for the regulation of wakefulness as well as REM sleep.

These observations suggest that main output regions of orexin neurons are monoaminergic/cholinergic neurons in the brain stem. Through these connections, orexins exert their physiological functions.

### **Differential Expression of Two Subtypes of Orexin Receptors**

Although it is clear that monoaminergic/cholinergic nuclei are important regions for orexin action, recent our observations suggest regulation of these nuclei by two subtypes of orexin receptors seems to be more complicated. As discussed earlier, the

TMN abundantly expressed *OXR-2* and the LC predominantly expressed *OXR-1*. In the LDT and PPT, expressions of both *OXR-1* and *OXR-2* were observed. Likewise, the dorsal and median raphe nuclei (DR and MnR), both *OXR-1* and *OXR-2* mRNA are expressed.

Notably in the TMN, we found that most of *OXR-2*-positive histaminergic neurons also express *Gad1* mRNA, suggesting that *OXR-2*-positive histaminergic neurons are also GABAergic. The majority of serotonergic neurons in the DR and MnR express both *OXR-1* and *OXR-2*. We also observed expressions of *OXR-1* or *OXR-2* mRNA in GABAergic neurons in the raphe nuclei. In the LC, all *OXR-1*-positive neurons are noradrenergic neurons.

In the LDT and PPT, *OXR-1* mRNA is expressed in all cholinergic neurons. Both *OXR-1* and *OXR-2* mRNA were found to be expressed in GABAergic neurons<sup>33</sup>.

These observations suggest that in the monoaminergic/cholinergic nuclei, two orexin receptors play distinct roles in regulating activity of neurons that constitutes the ARAS (Fig. 3).

## Sleep/wake regulation and orexins

### *Physiological roles of orexins on sleep/wake states*

Intracerebroventricular (ICV) injection of orexin A or orexin B in rats or mice during the light (rest) period potently increases awake time and decreases REM and non-REM (NREM) sleep time<sup>60</sup>. As discussed above, the projection pattern of orexin neurons and distributions of orexin receptor mRNAs suggests that main effector sites for orexin are monoaminergic/cholinergic neurons in the brainstem. Indeed, electrophysiological experiments showed that firing rates of monoaminergic cells in these nuclei are increased by orexins; Noradrenergic cells of the LC<sup>60-61</sup>, dopaminergic cells of the VTA<sup>62</sup>, serotonergic cells of the DR<sup>63-64</sup>, and histaminergic cells of the TMN<sup>65</sup> have all been shown to increase their firing rates by orexins. The firing rates of these monoaminergic neurons are strongly associated with sleep/wakefulness states: they fire tonically during awake period, less during NREM sleep, and cease firing during REM sleep<sup>66</sup>. These observations suggest that increased firing of these wake-active monoaminergic neurons mediates arousal induced by orexins.

Orexins also have strong direct excitatory effects on cholinergic neurons in the basal forebrain, which are important for maintaining arousal and attention<sup>67-68</sup>. In addition, orexin neurons project directly to the laterodorsal tegmental/pedunculopontine

tegmental nucleus (LDT/PPT) cholinergic neurons. Some populations of these cholinergic neurons are implicated in the maintenance of wakefulness and REM sleep (W/REM-on neurons)<sup>69</sup>, whereas other populations are implicated in desynchronization of cerebral cortex and muscle atonia during REM sleep (REM-on neurons)<sup>69</sup>. Direct injection of orexin A into the LDT of cats results in an increased awake time and a decreased REM sleep time<sup>70</sup>. In addition, several reports have shown that orexin induces long-lasting excitation of cholinergic neurons in the LDT<sup>71</sup>. However, recent work also showed that orexin A inhibits cholinergic neurons in the PPT via activation of GABAergic local interneurons and GABAergic neurons in the substantia nigra pars reticulata, which send inhibitory projections to the PPT<sup>39</sup>. In fact, as discussed earlier, we found robust expression of *OXR-1* in the cholinergic neurons, and both receptor expression in GABAergic neurons in these regions<sup>33</sup>. Consistently, orexin-A excites both cholinergic and non-cholinergic neurons of the LDT in slice preparations<sup>72</sup>. Taken together, these results indicate that in the LDT/PPT, orexin may activate W/REM-on cholinergic neurons through OX<sub>1</sub>R to facilitate wakefulness. Simultaneously, orexin might activate GABAergic interneurons to inhibit REM-on cholinergic neurons through activation of both receptors in these nuclei. Additionally, orexinergic activations of wake-active noradrenergic and serotonergic neurons in the LC and raphe nuclei through

OXR-1 and both receptors, respectively, are likely to counteract activation of REM-on cholinergic neurons in the LDT/PPT during wakefulness<sup>2, 73</sup>. This is consistent with the fact that tricyclic antidepressants and serotonin-specific reuptake inhibitors are effective for treating cataplexy in narcoleptic patients.

### *Orexin receptors in sleep and wakefulness*

It is believed that the effect of orexin on wakefulness is largely mediated by activation of the TMN histaminergic neurons that express OXR-2<sup>65, 74</sup>. *OXR-2* KO mice and *prepro-orexin* KO mice are similarly affected by behaviorally abnormal attacks of NREM sleep (“sleep attacks”)<sup>30</sup>, but *OXR-2* KO mice show a lower degree of disrupted wakefulness compared with double receptor KO (*OXR-1* - and *OXR-2* -null) mice<sup>2, 32, 75</sup>. In particular, *OXR-2* KO mice are only mildly affected by cataplexy and direct transitions to REM sleep from awake states<sup>30</sup>, as compared with orexin KO mice and double receptor KO mice<sup>12, 19 30</sup>. *Orexin* KO mice and double receptor KO mice have very similar phenotypes<sup>12,30</sup>. Thus, these observations suggest that *OXR-2* plays a pivotal role, but *OXR-1* has additional effects on sleep-wake regulation. The gating of REM sleep is likely to critically involve both receptors.



### ***Orexinergic activity in the sleep-wake cycle***

Transgenic mice in which orexin is constitutively expressed in a diffuse, ectopic pattern in the brain exhibit abnormal sleep and wakefulness patterns, including fragmented NREM sleep in the light period and incomplete REM sleep atonia with abnormal myoclonic activity during REM sleep<sup>76</sup>. These results suggest that firing rate of orexin neurons should be decreased or ceased to maintain consolidated NREM sleep and the muscle atonia that accompanies REM sleep.

Consistent with this idea, Fos expression (a marker of neuronal activity) in orexin neurons in rats is increased during the dark, active period in which the awake state is dominant<sup>77</sup>. Orexin levels in CSF peak during the dark period and decrease during the light period in which the sleep state is dominant<sup>78</sup>. Moreover, *in vivo* recording studies revealed changes of orexin neuronal activity across the sleep-wake cycle in rats or mice<sup>79-81</sup>. These studies showed that orexin neurons fire during active waking, decrease discharge during quiet waking, and virtually cease firing during both REM and NREM sleep.

### ***Mechanisms that underlie orexin-mediated stabilization of sleep/wakefulness states***

A reciprocal feedback loop between orexin neurons and monoaminergic neurons in the brainstem (including the LC and DR<sup>47, 49, 51</sup>) might maintain the activity of

monoaminergic neurons to stabilize wakefulness (Figure 2B). Wake-active monoaminergic centers are also influenced by the inhibitory projections from the POA, especially VLPO<sup>44</sup>. During sleep, VLPO sleep-active neurons are thought to be activated by sleep substances such as adenosine<sup>82-84</sup>. As discussed above, the sleep-active neurons also send inhibitory projections to hypothalamic orexin neurons<sup>8, 85</sup>. These triangular neural circuits might be important for stability of wakefulness.

Without orexin neurons, the balance between these waking-active neurons and sleep-active neurons in the POA is likely to be delicate, and sleep and wakefulness will turn into the alternative mode abruptly, as observed in narcolepsy.

### ***Dual center model of sleep/wake regulation***

The dual center hypothesis of feeding regulation, which was proposed about fifty years ago, states that the ventromedial hypothalamus (VMH) is the satiety center, whereas the LHA is the feeding center. Although later studies have shown that the regulatory mechanisms of feeding are more complex (involving a number of hypothalamic regions including the arcuate nucleus and dorsomedial hypothalamus), satiety and feeding is a balancing process between two major groups of neurochemical pathways .

Similarly, in sleep/wakefulness regulation, there seem to be two major groups of neural pathways that balance sleep and wakefulness. The effector mechanism that regulates cortical function is the monoaminergic/cholinergic neurons in the brainstem (ARAS), whose diffuse innervations to cerebral cortex play an important role in desynchronization of cortical neurons during wakefulness. Orexin neurons in the LHA appear to be the accelerator, whereas sleep-active neurons in the preoptic area are likely to be the decelerator of the ARAS to regulate cortical function and sleep/wake states.

### **Roles of orexins in feeding behavior and energy homeostasis**

Initially, orexins were recognized as regulators of feeding behavior because of their exclusive production in the LHA and their actions on food intake; ICV injection of orexins during the light period induces feeding behavior in rats and mice<sup>1, 59, 86-87</sup>.

In addition, orexin mRNA expression was shown to increase during fasting<sup>1</sup>. A transcription factor *Foxa2* is likely to mediate this phenomenon by translocating into the nucleus, binding to orexin promoter, and subsequently stimulating transcription of orexin gene in response to fasting<sup>88</sup>.

Genetic studies have also shown that orexins play a role in the regulation of energy homeostasis. For example, orexin neuron-ablated mice display hypophagia and

late-onset obesity, although the extent of abnormality critically depends on the genetic backgrounds of the mice<sup>21, 89</sup>. Furthermore, narcolepsy patients have a decreased caloric intake but an increased body mass index (BMI)<sup>90-91</sup>. The orexin system is likely to positively regulate feeding as well as arousal, activity, and basal energy expenditure, and this might explain why narcoleptic mice and humans show increased body weight despite their hypophagia.

Supporting the physiological relevance of orexin in the control of feeding, ICV administration of an anti-orexin antibody or an OXR-1-selective antagonist reduced food intake<sup>59, 92</sup>.

OXR-2-mediated pathways might also be important for energy homeostasis<sup>93</sup>. Transgenic mice with ubiquitous orexin overexpression are resistant to high-fat diet-induced obesity and insulin insensitivity by promoting energy expenditure and reducing consumption. Genetic and pharmacological studies indicated that OXR-2 (rather than OXR-1) signaling, predominantly mediates this phenotype through negative energy homeostasis and improved leptin sensitivity<sup>93</sup>.

Consistent with the dense projection of orexin neurons to the Arc<sup>15, 17, 94</sup>, several studies have suggested that the increased food intake following orexin A administration is at least partly mediated by activation of neuropeptide Y (NPY)

neurons in the Arc<sup>94-95</sup>. Other events involved in orexin-induced feeding behavior include inhibition of proopiomelanocortin (POMC) neurons in the Arc, which are thought to play an important role in leptin-mediated inhibition of food intake<sup>95</sup>. Recent reports also showed that infusions of orexin A into the shell of the nucleus accumbens (NAc) increase feeding behavior<sup>96</sup>. In addition, infusions of the GABA<sub>A</sub> receptor agonist muscimol into the NAc shell strongly induced food intake and simultaneously increased Fos expression specifically in orexin neurons<sup>97</sup>. These findings suggest that reciprocal interactions between the orexin and limbic systems play a role in the regulation of feeding. In addition, the orexin system stimulates feeding-associated glucose utilization in skeletal muscle by activation of sympathetic nervous system through acting on the VMH<sup>98</sup>.

As discussed above, orexin-mediated maintenance of consolidated wakefulness might also be important in feeding behavior, because maintenance of arousal during food searching and intake is essential for an animal's survival<sup>4</sup>. In other words, if energy stores are low, firing rate of orexin neurons might be increased to maintain wakefulness, allowing more time to search for food.

## Other Functions

Orexin system has been also implicated in many other systems, such as reward system, autonomic nervous system, and stress response. In this review, we will just briefly mention these functions. Please refer to another review for detailed descriptions<sup>2</sup>.

#### *Orexin and the autonomic nervous system*

Several studies clearly showed that orexins play a role in mobilizing sympathetic responses. It has been demonstrated that ICV orexin injections increase blood pressure and heart rate, and that these effects are abolished by administration of drugs that block  $\alpha$ - or  $\beta$ -adrenoceptors<sup>99</sup>. Moreover, blood pressure in orexin-deficient mice is 10-15 mmHg lower than in wild-type littermates<sup>100</sup>. As discussed earlier, the orexin-mediated increase in sympathetic tone might also be involved in the mechanisms by which the limbic system modulates the sympathetic outflow responding to emotional stimuli<sup>36, 101</sup>.

#### *Orexin and the reward system*

Activation of orexin neurons was shown to be strongly linked to preferences for cues associated with drug and food rewards<sup>9</sup>. ICV or local VTA infusions of orexins have been shown to reinstate drug-seeking or food-seeking behavior in rodents<sup>3, 9</sup>.

Conversely, the subcutaneous morphine (mu opioid receptor agonist)-induced place preference and hyperlocomotion observed in wild-type mice were abolished in mice that lacked the *prepro-orexin* gene<sup>10</sup>, and injections of an OXR-1 antagonist into the VTA

block the development of morphine-conditioned place preference<sup>10</sup>. These observations suggest the strong functional interaction between orexinergic pathways and the dopaminergic system. *In vivo* administration of an OXR-1 antagonist blocks locomotor sensitization to cocaine and occludes cocaine-induced potentiation of excitatory currents in VTA dopamine neurons<sup>102</sup>. These results suggest an important role for orexin signaling in the VTA in the neural plasticity associated with reward, and indicate that orexins also contribute to cocaine-induced psychomotor sensitization and reward-seeking. Interestingly, some narcolepsy patients with daytime sleepiness who had been treated with amphetamine-like stimulants and/or sodium oxybate (gamma hydroxybutyrate, also known as GHB) for a long time, rarely developed drug abuse<sup>103</sup>.

## Therapeutic potential of drugs that target orexin receptors

### *Orexin receptor antagonists*

Orexin initially drew attention as a regulator of food intake. Therefore, several pharmaceutical companies developed orexin receptor antagonists to control appetite for obesity treatment. Indeed, an OXR-1-selective antagonist reduced food intake and ameliorated obesity in leptin-deficient *ob/ob* mice<sup>86</sup>.

Subsequently, because orexins have been implicated in the maintenance of

arousal, several companies have been exploring the possibility of using orexin receptor antagonists as drugs for insomnia treatment. To date, several orexin receptor antagonists with different pharmacological characteristics have been developed (Table 1). A first-in-class dual orexin receptor antagonist almorexant (ACT-078573, Actelion Pharmaceuticals Ltd) was recently developed. It blocks both OXR-1 and OXR-2 with almost equimolar potency (IC<sub>50</sub> of 16 and 15 nM, respectively). It reduces time spent in wake states and enables and maintains sleep in rats, dogs, and humans<sup>104-105</sup>. Recently, the results of a study on almorexant in 147 patients with primary insomnia were reported<sup>105</sup>. The drug significantly improved the primary parameter of sleep efficiency (time spent sleeping while confined to bed during an eight hour period at night) in a dose-dependent manner. Almorexant decreased latency to sleep onset and number of wake bouts after sleep onset. Importantly, Actelion reports that almorexant not only changed these physiological sleep parameters, but also significantly improved subjective sleep qualities. Effective doses of almorexant did not cause any relevant negative effects on next-day performance (assessed by fine motor testing and mean reaction time), as is commonly observed with current insomnia treatments such as benzodiazepines which are GABA receptor modulators. In addition, it was reported that rats treated with administration of high doses of almorexant (300 mg/kg, p.o.), are fully



capable of spatial and avoidance learning<sup>106</sup>. Importantly, almorexant increases time spent in REM sleep, which is thought to be of key importance for our ability to store and process information. However, at the same time the effect of REM period elongation might cause unwanted complications such as vivid dreaming, nightmare and sleep paralysis. Notably, almorexant was well tolerated with no signs of cataplexy, suggesting that acute, short-lived, intermittent temporary blockage of orexin receptors will not result in a narcolepsy-like phenotype<sup>107</sup>.

MK-4305 is a compound 10 with a 7-methyl substitution on the diazepane core with a potent dual orexin receptor antagonistic activity. This compound is also now under the phase III clinical trials for the treatment of primary insomnia.

Recently, administrations of an OXR-2 selective antagonist JNJ-10397049 were shown to decrease the latency for persistent sleep and increased NREM sleep time more potently than the dual antagonist almorexant<sup>108</sup>. Administrations of an OXR-1 selective antagonist SB-408124 had no effect on sleep parameters. Rather, the OXR-1 antagonist attenuated the sleep-promoting effects of OXR-2 antagonist when simultaneously administered, possibly by increasing dopamine release in the prefrontal cortex. Thus, selective OXR-2 antagonists may offer an advantage for the treatment of insomnia. As discussed earlier, OXR-1 and OXR-2 are differentially distributed in the

monoaminergic/cholinergic regions, suggesting distinct physiological roles of these receptors. Further research using selective antagonists and/or each receptor KO mouse would be required to understand effectiveness, advantages and disadvantages of these compounds.

It has been shown that orexin mediates many behaviours associated with drug addiction in rodents due to its effects on the VTA<sup>109</sup>. Recent report showed that orexin-1 receptor antagonist SB-334867 reduces the acquisition and expression of cocaine-conditioned reinforcement and the expression of amphetamine-conditioned reward, suggesting that OXR1-selective antagonists have the potential to be a treatment for individuals struggling with drug relapse and dependency<sup>110</sup>. Although whether the effects of orexin are the same in humans is still unknown, it is reasonable to speculate that orexin receptor antagonists might be effective for treating drug addiction. This notion is supported by the fact that drug addiction is seldom found in narcolepsy patients who are treated with psychostimulants.

OXR-1 antagonists might also be effective for panic disorders. They inhibit elevations of mean arterial pressure, heart rates and freezing responses in rat models of panic disorder<sup>111</sup>.

### *Orexin Receptor Agonists*

Because narcolepsy-cataplexy results from the absence of orexin, replacement therapy using orexin receptor agonists could be valuable for treating narcolepsy. These drugs might also be effective in other conditions of excessive daytime sleepiness. Indications that this might be successful come from a study demonstrating that chronic overproduction of orexin peptides from an ectopically expressed transgene prevented the development of a narcolepsy syndrome in orexin neuron-ablated (*orexin/ataxin-3*-transgenic) mice<sup>112</sup>. Acute ICV administration of orexin A also maintained wakefulness, suppressed sleep, and inhibited cataplectic attacks in *orexin/ataxin-3* mice<sup>112</sup>. ICV administration of orexin-A has stronger arousal effects in *orexin/ataxin-3* transgenic mice than in wild-type controls<sup>112</sup>. The greater effectiveness might not result from increased expression of orexin receptors<sup>112</sup>. Rather, in the *orexin/ataxin-3* mice, monoaminergic neurons in the brainstem become more sensitive to various stimuli (our unpublished results). This mechanism might explain why narcoleptics cannot maintain long consolidated NREM sleep periods.

Effectiveness of ICV orexin to narcoleptic phenotype suggests orexin receptor agonists would be of potential value for treating narcolepsy. However, as mentioned

before, chronic overexpression of orexin in an unregulated fashion results in disruption of NREM sleep, and therefore, it will be beneficial for therapeutically relevant orexin agonists to have a short half-life (<12 hr).

### **Conclusion and perspectives**

The symptoms and the cellular and systems-level bases of narcolepsy-cataplexy unequivocally show that orexins and orexin receptors are important regulators of sleep and wakefulness and of arousal maintenance by regulating monoaminergic and cholinergic nuclei in the brain. Orexin neurons receive afferents from multiple neuronal systems, and send excitatory signals to monoaminergic and cholinergic nuclei in the brainstem. Understanding connectomics of orexin neurons more precisely might provide further insights into how the systems regulating emotion, energy homeostasis and reward interact with the mechanism that regulates sleep and wakefulness. Further studies dissecting roles of each receptor in particular brain regions, by means of spatially-restricted deletion of each receptor gene, as well as specific regional rescue of each receptor to receptor KO mice, might shed light on the mechanisms of action of these peptides.

**FIG. 1 Orexin and orexin receptors.** (A) Structures of various species of orexin A and orexin B. The topology of the two intrachain disulfide bonds of orexin A is indicated above the sequence. Shadows indicate amino acid identity. Mammalian orexin A sequences thus far identified (human, rat, mouse, pig, dog, sheep, cow) are all identical.

(B) Orexin A and orexin B are derived from a common precursor peptide, prepro-orexin. The actions of orexins are mediated via two G protein-coupled receptors named orexin-1 (OXR-1) and orexin-2 (OXR-2) receptors. OXR-1 is selective for orexin A, whereas OXR-2 show similar affinities for both orexin A and orexin B. OXR-1 is coupled to the Gq subclass of heterotrimeric G proteins, whereas OXR-2 couples to Gi/o and /or Gq in cell lines.

**Fig 2. Connections of orexin neurons with other regions.** Orexin neurons in the lateral hypothalamic area (LHA) provide a link between the limbic system, energy homeostasis and the brain stem nuclei. **A.** Major projections of orexin neurons. Modified from Sakurai 2007<sup>2</sup>. Circles show major target sites for orexins. Included in these are the locus coeruleus (LC, containing noradrenaline, NA), tuberomammillary nucleus (TMN, containing histamine, HA), raphe nuclei (Raphe, containing 5-HT), ventral tegmental area (VTA, containing dopamine, DA), and laterodorsal/pedunclopontine tegmental nuclei (PPT/LDT, containing acetylcholine, Ach). Orexin neurons promote wakefulness through the monoaminergic/cholinergic nuclei that are wake-active. **B.** Schematic presentations of output and input of orexin neurons shown in regions of rectangle in (A). Connection between dopaminergic centers and orexin neurons plays to modulate the reward systems. Input from the limbic system might be important to regulate the activity of orexin neurons upon emotional stimuli to evoke emotional arousal or fear-related responses. Sleep-active neurons in the POA send inhibitory influences to monoaminergic/cholinergic neurons and orexin neurons. Orexin neurons send both direct excitatory input to cholinergic neurons in the LDT/PPT and indirect inhibitory input to these cells through GABAergic local interneurons and GABAergic neurons in the substantia nigra pars reticulata<sup>39</sup>. Noradrenergic neurons in

the LC and serotonergic neurons in the RN also send inhibitory influences to these cholinergic neurons. Blood glucose levels also affect the activity of orexin neurons through fluctuations of glucose levels in the CSF and vagal afferent.

NAc, nucleus accumbens; PVH, paraventricular hypothalamic nucleus; TMN, tuberomammillary nucleus; LHA, lateral hypothalamic area; DMH, dorsomedial hypothalamus; ARC, arcuate nucleus; VTA, ventral tegmental area; SN, substantia nigra; SCN, suprachiasmatic nucleus; RN, raphe nucleus; LC, locus coeruleus; PPT, pedunculo pontine tegmental nucleus; LDT, laterodorsal tegmental nucleus

Fig. 3. Schematic illustration of presumed pathways underlying orexin actions on NREM and REM sleep<sup>33</sup>. Orexins activate histaminergic (His)/GABAergic (GA), serotonergic (5HT), noradrenergic (NA), and cholinergic (ACh) neurons, as well as GABAergic putative interneurons, in wake-promoting nuclei, including the TMN, DR/MnR, LDT/PPT, and LC. These neurons differentially express OXR-1 and/or OXR-2, and regulate wakefulness/NREM sleep and NREM/REM sleep transitions. OXR-1 and OXR-2 may be expressed in the same populations of GABAergic neurons, as shown in the figure, or may be expressed in distinct populations of these neurons in each area. Wake/REM-on cholinergic neurons (ACh/W) are likely to suppress NREM

sleep but REM-on cholinergic neurons (ACh/R) are likely to induce REM sleep. Wake-active serotonergic and noradrenergic neurons in the DR/MnR and LC, respectively, counteract activation of REM-on cholinergic neurons in the LDT/PPT, as well as REM-on neurons in the brainstem reticular formation<sup>2,71</sup>. Previous reports have suggested contributions of GABAergic interneurons inhibiting PPT cholinergic and raphe serotonergic neurons<sup>39,62</sup>. LHA, lateral hypothalamic area; PH, posterior hypothalamus.



|               | Compound  | Affinity               |                        | Units             | Ref            |
|---------------|---|------------------------|------------------------|-------------------|----------------|
|               |   | OXR-1                  | OXR-2                  |                   |                |
| DORA          | ACT-078573 (almorexant)   | 7.9 (human), 7.8 (rat) | 8.1 (human), 7.8 (rat) | pIC <sub>50</sub> | <sup>104</sup> |
| DORA          | MK-4305   | 9.26                   | 9.46                   | pK <sub>i</sub>   | <sup>113</sup> |
| OXR-1<br>SORA | SB-410220   | 7.7                    | nd                     | pK <sub>i</sub>   | <sup>114</sup> |
| OXR-1<br>SORA | SB-334867   | 7.2                    | nd                     | pK <sub>i</sub>   | <sup>114</sup> |
| OXR-1<br>SORA | SB-408124   | 7                      | nd                     | pK <sub>i</sub>   | <sup>114</sup> |
| OXR-1<br>SORA | [3H]SB-674042   | 8.3                    | nd                     | pK <sub>d</sub>   | <sup>114</sup> |
| OXR-1<br>SORA | SB-410220   | 8.1                    | 6.3                    | pK <sub>b</sub>   | <sup>114</sup> |
| OXR-1<br>SORA | SB-334867   | 7.4                    | 5.7                    | pK <sub>b</sub>   | <sup>115</sup> |
| OXR-1<br>SORA | SB-408124   | 7.7                    | 5.9                    | pK <sub>b</sub>   | <sup>114</sup> |
| OXR-1<br>SORA | SB-674042   | 9                      | 6.9                    | pK <sub>b</sub>   | <sup>114</sup> |
| OXR-2<br>SORA | 1-(2-bromo-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea                    | 5.3 – 6.1              | 6.8 – 7.1              | pK <sub>i</sub>   | <sup>116</sup> |
| OXR-2<br>SORA | 1-(2,4-dibromo-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea (JNJ-10397049) | 5.3 – 5.8              | 8.0 – 8.6              | pK <sub>i</sub>   | <sup>116</sup> |

Table 1 List of available orexin receptor antagonists. SORA, single orexin receptor antagonist; DORA, dual orexin receptor antagonist

## References

1. Sakurai, T., *et al.* (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell* 92, 573-585
2. Sakurai, T. (2007) The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. *Nat Rev Neurosci* 8, 171-181
3. Boutrel, B., *et al.* (2005) Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. *Proc Natl Acad Sci USA*. 102, 19168-19173
4. Yamanaka, A., *et al.* (2003) Hypothalamic orexin neurons regulate arousal according to energy balance in mice. *Neuron* 38, 701-713
5. Akiyama, M., *et al.* (2004) Reduced food anticipatory activity in genetically orexin (hypocretin) neuron-ablated mice. *Eur J Neurosci*. 20, 3054-3062.
6. Mieda, M., *et al.* (2004) Orexin neurons function in an efferent pathway of a food-entrainable circadian oscillator in eliciting food-anticipatory activity and wakefulness. *J Neurosci*. 24, 10493-10501
7. Sakurai, T., *et al.* (2005) Input of Orexin/Hypocretin Neurons Revealed by a Genetically Encoded Tracer in Mice. *Neuron* 46, 297-308
8. Yoshida, K., *et al.* (2006) Afferents to the orexin neurons of the rat brain. *J Comp Neurol*. 494, 845-861
9. Harris, G.C., *et al.* (2005) A role for lateral hypothalamic orexin neurons in reward seeking. *Nature* 437, 556-559
10. Narita, M., *et al.* (2006) Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. *J Neurosci*. 26, 398-405
11. de Lecea, L., *et al.* (1998) The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. *Proc Natl Acad Sci USA*. 95, 322-327
12. Willie, J.T., *et al.* (2001) To eat or to sleep? Orexin in the regulation of feeding and wakefulness. *Annu Rev Neurosci*. 24, 429-458
13. Zhu, Y., *et al.* (2003) Orexin receptor type-1 couples exclusively to pertussis toxin-insensitive G-proteins, while orexin receptor type-2 couples to both pertussis toxin-sensitive and -insensitive G-proteins. *J Pharmacol Sci*. 92, 259-266.
14. Marcus, J.N., *et al.* (2001) Differential expression of orexin receptors 1 and 2 in the rat brain. *J Comp Neurol*. 435, 6-25
15. Peyron, C., *et al.* (1998) Neurons containing hypocretin (orexin) project to multiple neuronal systems. *J Neurosci*. 18, 9996-10015

16. Nambu, T., *et al.* (1999) Distribution of orexin neurons in the adult rat brain. *Brain Res.* 827, 243-260
17. Date, Y., *et al.* (1999) Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. *Proc Natl Acad Sci U S A.* 96, 748-753
18. Mignot, E. (1998) Genetic and familial aspects of narcolepsy. *Neurology* 50, S16-S22
19. Chemelli, R.M., *et al.* (1999) Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. *Cell* 98, 437-451
20. Lin, L., *et al.* (1999) The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. *Cell* 98, 365-376
21. Hara, J., *et al.* (2001) Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. *Neuron* 30, 345-354
22. Peyron, C., *et al.* (2000) A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. *Nat. Med.* 9, 991-997
23. Thannickal, T.C., *et al.* (2000) Reduced number of hypocretin neurons in human narcolepsy. *Neuron* 27, 469-474
24. Mignot, E., *et al.* (2002) The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. *Arch Neurol.* 59, 1553-1562
25. (2005) *The International Classification of Sleep Disorders: Diagnostic and Coding Manual.* Rochester
26. Kadotani, H., *et al.* (1998) Genetic studies in the sleep disorder narcolepsy. *Genome Res.* 8, 427-434
27. Cvetkovic-Lopes, V., *et al.* (2010) Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. *J Clin Invest* 120, 713-719
28. Hallmayer, J., *et al.* (2009) Narcolepsy is strongly associated with the T-cell receptor alpha locus. *Nat Genet* 41, 708-711
29. Miyagawa, T., *et al.* (2008) Variant between CPT1B and CHKB associated with susceptibility to narcolepsy. *Nat Genet* 40, 1324-1328
30. Willie, J.T., *et al.* (2003) Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. *Neuron* 38, 715-730
31. Zeitzer, J.M., *et al.* (2006) The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions. *Trends Pharmacol Sci.* 27, 368-374
32. Willie, J.T., *et al.* (2003) Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory

processes. *Neuron* 38, 715-730

33. Mieda, M., *et al.* (2011) Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep. *J. Neurosci.* in press
34. Winsky-Sommerer, R., *et al.* (2004) Interaction between the corticotropin-releasing factor system and hypocretins (orexins): a novel circuit mediating stress response. *J Neurosci.* 24, 11439-11448
35. Kayaba, Y., *et al.* (2003) Attenuated defense response and low basal blood pressure in orexin knockout mice. *Am. J. Physiol.Regul. Integr. Comp. Physiol.* 285, R581-593
36. Zhang, W., *et al.* (2006) Orexin neuron-mediated skeletal muscle vasodilation and shift of baroreflex during defense response in mice. *Am J Physiol Regul Integr Comp Physiol.* in press
37. Zhang, W., *et al.* (2009) Orexin neurons in the hypothalamus mediate cardiorespiratory responses induced by disinhibition of the amygdala and bed nucleus of the stria terminalis. *Brain Res* 1262, 25-37
38. Ponz, A., *et al.* (2010) Reduced amygdala activity during aversive conditioning in human narcolepsy. *Ann Neurol* 67, 394-398
39. Takakusaki, K., *et al.* (2005) Orexinergic projections to the midbrain mediate alternation of emotional behavioral states from locomotion to cataplexy. *J Physiol.* 568(Pt 3), 1003-1020
40. Shiromani, P.J., *et al.* (1988) Distribution of choline acetyltransferase immunoreactive somata in the feline brainstem: implications for REM sleep generation. *Sleep* 11, 1-16
41. Berthoud, H.R. (2004) Mind versus metabolism in the control of food intake and energy balance. *Physiol Behav.* 81, 781-793
42. Reid, M.S., *et al.* (1998) Neuropharmacological characterization of basal forebrain cholinergic stimulated cataplexy in narcoleptic canines. *Exp Neurol.* 151, 89-104
43. Sherin, J.E., *et al.* (1998) Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat. *J Neurosci.* 18, 4705-4721
44. Lu, J., *et al.* (2002) Selective activation of the extended ventrolateral preoptic nucleus during rapid eye movement sleep. *J Neurosci.* 22, 4568-4576
45. Xie, X., *et al.* (2006) GABA(B) receptor-mediated modulation of hypocretin/orexin neurones in mouse hypothalamus. *J Physiol.* 574, 399-414
46. Matsuki, T., *et al.* (2009) Selective loss of GABA(B) receptors in orexin-producing neurons results in disrupted sleep/wakefulness architecture. *Proc Natl Acad Sci U S A.* 106, 4459-4464

47. Muraki, Y., *et al.* (2004) Serotonergic regulation of the orexin/hypocretin neurons through the 5-HT<sub>1A</sub> receptor. *J. Neurosci.* 24, 7159-7166
48. Sakurai, T. (2005) Reverse pharmacology of orexin: from an orphan GPCR to integrative physiology. *Regul Pept* 126, 3-10
49. Yamanaka, A., *et al.* (2006) Orexin neurons are directly and indirectly regulated by catecholamines in a complex manner *J. Neurophysiol.* 96, 284-298
50. Li, Y., *et al.* (2002) Hypocretin/Orexin excites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hypothalamic arousal system. *Neuron* 36, 1169-1181
51. Yamanaka, A., *et al.* (2003) Regulation of orexin neurons by the monoaminergic and cholinergic systems. *Biochem Biophys Res Commun.* 303, 120-129
52. Tsujino, N., *et al.* (2005) Cholecystokinin activates orexin/hypocretin neurons through the cholecystokinin A receptor. *J Neurosci.* 25, 7459-7469
53. Furutani, N., *et al.* (2010) Activation of bombesin receptor subtype-3 influences activity of orexin neurons by both direct and indirect pathways. *J Mol Neurosci* 42, 106-111
54. Yamanaka, A., *et al.* (2010) Orexin directly excites orexin neurons through orexin 2 receptor. *J Neurosci* 30, 12642-12652
55. Burdakov, D., *et al.* (2005) Physiological changes in glucose differentially modulate the excitability of hypothalamic melanin-concentrating hormone and orexin neurons in situ. *J Neurosci.* 25, 2429-2433
56. Burdakov, D., *et al.* (2006) Tandem-pore K<sup>+</sup> channels mediate inhibition of orexin neurons by glucose. *Neuron* 50, 711-722
57. Cai, X.J., *et al.* (2001) Hypoglycemia activates orexin neurons and selectively increases hypothalamic orexin-B levels: responses inhibited by feeding and possibly mediated by the nucleus of the solitary tract. *Diabetes* 50, 105-112
58. Williams, G., *et al.* (2001) The hypothalamus and the control of energy homeostasis: different circuits, different purposes. *Physiol Behav.* 74, 683-701
59. Haynes, A.C., *et al.* (2000) A selective orexin-1 receptor antagonist reduces food consumption in male and female rats. *Regul Pept.* 96, 45-51
60. Hagan, J.J., *et al.* (1999) Orexin A activates locus coeruleus cell firing and increases arousal in the rat. *Proc Natl Acad Sci U S A.* 96, 10911-10916
61. Horvath, T.L., *et al.* (1999) Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. *J Comp Neurol.* 415, 145-159
62. Nakamura, T., *et al.* (2000) Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. *Brain Res.* 873, 181-187
63. Liu, R.J., *et al.* (2002) Hypocretins (orexins) regulate serotonin neurons in the

- dorsal raphe nucleus by excitatory direct and inhibitory indirect actions. *J. Neurosci.* 22, 9453-9464
64. Brown, R.E., *et al.* (2002) Convergent excitation of dorsal raphe serotonin neurons by multiple arousal systems (orexin/hypocretin, histamine and noradrenaline). *J. Neurosci.* 22, 8850-8859
65. Yamanaka, A., *et al.* (2002) Orexins activate histaminergic neurons via the orexin 2 receptor. *Biochem Biophys Res Commun.* 290, 1237-1245
66. Vanni-Mercier, G., *et al.* (1984) Neurons spécifiques de l'éveil dans l'hypothalamus postérieur du chat. *C.R. Acad. Sci., III* 298, 195-200
67. Eggermann, E., *et al.* (2001) Orexins/hypocretins excite basal forebrain cholinergic neurones. *Neuroscience* 108, 177-181
68. Alam, M.N., *et al.* (1999) Adenosinergic modulation of rat basal forebrain neurons during sleep and waking: neuronal recording with microdialysis. *J Physiol.* 521, 679-690
69. Shouse, M.N., and Siegel, J.M. (1992) Pontine regulation of REM sleep components in cats: integrity of the pedunclopontine tegmentum (PPT) is important for phasic events but unnecessary for atonia during REM sleep. *Brain Res.* 571, 50-63
70. Xi, M., *et al.* (2001) Effects on sleep and wakefulness of the injection of hypocretin-1 (orexin-A) into the laterodorsal tegmental nucleus of the cat. *Brain Res.* 901, 259-264
71. Takahashi, K., *et al.* (2002) Effects of orexin on the laterodorsal tegmental neurones. *Psychiatry Clin Neurosci.* 56., 335-336
72. Burlet, S., *et al.* (2002) Direct and indirect excitation of laterodorsal tegmental neurons by hypocretin/orexin peptides: Implication for wakefulness and Narcolepsy. *J. Neurosci.* 22, 2862-2872
73. Pace-Schott, E.F., and Hobson, J.A. (2002) The neurobiology of sleep: genetics, cellular physiology and subcortical networks. *Nat Rev Neurosci* 3, 591-605
74. Huang, Z.L., *et al.* (2001) Arousal effect of orexin A depends on activation of the histaminergic system. *Proc. Natl. Acad. Sci. U. S. A.* 98, 9965-9970
75. Hondo, M., *et al.* (2010) Histamine-1 receptor is not required as a downstream effector of orexin-2 receptor in maintenance of basal sleep/wake states. *Acta Physiol (Oxf)* 198, 287-294
76. Willie, J.T., *et al.* (2010) Ectopic Overexpression of Orexin Alters Sleep/Wakefulness States and Muscle Tone Regulation during REM Sleep in Mice. *J Mol Neurosci*
77. Estabrooke, I.V., *et al.* (2001) Fos expression in orexin neurons varies with behavioral state. *J Neurosci.* 21, 1656-1662
78. Yoshida, Y., *et al.* (2001) Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. *Eur J Neurosci.* 14,

1075-1081

79. Mileykovskiy, B.Y., *et al.* (2005) Behavioral correlates of activity in identified hypocretin/orexin neurons. *Neuron* 46, 787-798
80. Lee, M.G., *et al.* (2005) Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. *J Neurosci.* 25, 6716-6720
81. Takahashi, K., *et al.* (2008 ) Neuronal activity of orexin and non-orexin waking-active neurons during wake-sleep states in the mouse. *Neuroscience* 153, 860-870
82. Morairty, S., *et al.* (2004) Disinhibition of ventrolateral preoptic area sleep-active neurons by adenosine:  
a new mechanism for sleep promotion. *Neuroscience* 123, 451-457
83. Arrigoni, E., *et al.* (2006) Adenosine inhibits basal forebrain cholinergic and noncholinergic neurons in vitro. . *Neuroscience* 140, 403-413
84. Huang, Z.L., *et al.* (2005) Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. *Nature Neuroscience* 8, 858-859
85. Sakurai, T. (2006) Roles of orexins and orexin receptors in central regulation of feeding behavior and energy homeostasis. *CNS Neurol Disord Drug Targets.* 5, 313-325
86. Haynes, A.C., *et al.* (2002) Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice. *Regul Pept.* 104, 153-159
87. Edwards, C.M., *et al.* (1999) The effect of the orexins on food intake: comparison with neuropeptide Y, melanin-concentrating hormone and galanin. *J. Endocrinol.* 160, R7-12
88. Silva, J.P., *et al.* (2009) Regulation of adaptive behaviour during fasting by hypothalamic Foxa2. *Nature* 462, 646-650
89. Hara, J., *et al.* (2005) Difference in obesity phenotype between orexin-knockout mice and orexin neuron-deficient mice with same genetic background and environmental conditions. *Neuroscience Letters* 380, 239-242
90. Schuld, A., *et al.* (2000) Increased body-mass index in patients with narcolepsy. *Lancet.*, 1274-1275
91. Lammers, G.J., *et al.* (1996) Spontaneous food choice in narcolepsy. *Sleep* 19, 75-76
92. Yamada, H., *et al.* (2000) Inhibition of food intake by central injection of anti-orexin antibody in fasted rats. *Biochem Biophys Res Commun.* 267, 527-531
93. Funato, H., *et al.* (2009) Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivity. *Cell Metab* 9, 64-76
94. Yamanaka, A., *et al.* (2000) Orexin-induced food intake involves neuropeptide Y pathway. *Brain Res.* 24, 404-409
95. Muroya, S., *et al.* (2004) Orexins (hypocretins) directly interact with neuropeptide Y,

POMC and glucose-responsive neurons to regulate Ca<sup>2+</sup> signaling in a reciprocal manner to leptin: orexigenic neuronal pathways in the mediobasal hypothalamus. *Eur J Neurosci.* 19, 1524-1534

96. Thorpe, A.J., and Kotz, C.M. (2005) Orexin A in the nucleus accumbens stimulates feeding and locomotor activity. *Brain Res.* 1050, 156-162

97. Baldo, B.A., *et al.* (2004) Activation of a subpopulation of orexin/hypocretin-containing hypothalamic neurons by GABAA receptor-mediated inhibition of the nucleus accumbens shell, but not by exposure to a novel environment. *Eur J Neurosci.* 19, 376-386

98. Shiuchi, T., *et al.* (2009) Hypothalamic orexin stimulates feeding-associated glucose utilization in skeletal muscle via sympathetic nervous system. *Cell Metab* 10, 466-480

99. Shirasaka, T., *et al.* (1999) Sympathetic and cardiovascular actions of orexins in conscious rats. *Am. J. Physiol.* 277, R1780-R1785

100. Zhang, W., *et al.* (2006) Orexin neuron-mediated skeletal muscle vasodilation and shift of baroreflex during defense response in mice. *Am J Physiol Regul Integr Comp Physiol.* 290, R1654-1663

101. Kayaba, Y., *et al.* (2003) Attenuated defense response and low basal blood pressure in orexin knockout mice. *Am J Physiol Regul Integr Comp Physiol.* 285, R581-593

102. Borgland, S.L., *et al.* (2006) Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. *Neuron* 49, 589-601

103. Guilleminault, C., *et al.* (1974) On the treatment of rapid eye movement narcolepsy. *Arch Neurol.* 30, 90-93

104. Brisbare-Roch, C., *et al.* (2007) Promotion of sleep by targeting the orexin system in rats, dogs and humans. *Nat Med* 13, 150-155

105. Hoever, P., *et al.* (2010) Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. *Clin Pharmacol Ther* 87, 593-600

106. Dietrich, H., and Jenck, F. (2010) Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant. *Psychopharmacology (Berl)* 212, 145-154

107. Neubauer, D.N. (2010) Almorexant, a dual orexin receptor antagonist for the treatment of insomnia. *Curr Opin Investig Drugs* 11, 101-110

108. Dugovic, C., *et al.* (2009) Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. *J Pharmacol Exp Ther* 330, 142-151

109. Harris, G.C., *et al.* (2007) Lateral hypothalamic orexin neurons are critically involved in learning to associate an environment with morphine reward. *Behav Brain Res* 183, 43-51



110. Hutcheson, D.M., *et al.* (2011) Orexin-1 receptor antagonist SB-334867 reduces the acquisition and expression of cocaine-conditioned reinforcement and the expression of amphetamine-conditioned reward. *Behav Pharmacol* 22, 173-181
111. Johnson, P.L., *et al.* (2010) A key role for orexin in panic anxiety. *Nat Med* 16, 111-115
112. Mieda, M., *et al.* (2004) Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. *Proc Natl Acad Sci U S A.* 101, 4649-4654
113. Cox, C.D., *et al.* (2010) Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-1,2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. *J Med Chem* 53, 5320-5332
114. Langmead, C.J., *et al.* (2004) Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. *Br J Pharmacol* 141, 340-346
115. Porter, R.A., *et al.* (2001) 1,3-Biarylyureas as selective non-peptide antagonists of the orexin-1 receptor. *Bioorg Med Chem Lett* 11, 1907-1910
116. McAtee, L.C., *et al.* (2004) Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists. *Bioorg Med Chem Lett* 14, 4225-4229


# A

orexin-A\*




human orexin-B

pig/dog/sheep/cow orexin-B


rat/mouse orexin-B



# B



A



B

